Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 2/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | GRM5 | P41594 | 4/20 | 0.49 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702612 | 0.83 | CA12 (0.66) | KCNH2APPRELACA12CA1 | |
| SCHEMBL28751450 | 0.81 | KCNH2 (0.51) | KCNH2GRM5 | |
| SCHEMBL28660450 | 0.81 | APP (0.63) | KCNH2APPCA12CA1CA2 | |
| SCHEMBL30081497 | 0.81 | KCNH2 (0.58) | KCNH2APPGRM5HAO1 | |
| SCHEMBL28630419 | 0.81 | KCNH2 (0.58) | KCNH2APPGRM5HAO1 | |
| SCHEMBL30707869 | 0.80 | KCNH2 (0.67) | KCNH2APPGRM5HAO1 | |
| SCHEMBL4562631 | 0.80 | KCNH2 (0.67) | KCNH2APPGRM5HAO1 | |
| Ammonia Solution, Strong SCHEMBL5555414 | 0.79 | KCNH2 (0.56) | KCNH2APPGRM5HAO1 | |
| SCHEMBL17469614 | 0.79 | APP (0.67) | KCNH2APPCA12CA1CA2 | |
| SCHEMBL6314495 | 0.79 | KCNH2 (0.53) | KCNH2APPRELACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| CN-1608065-A | Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase and pharmaceutical compositions containing the compounds | SMITHKLINE BEECHAM CORP (US) | 2005-04-20 | — | — | CN | disclosed |
| US-20050014938-A1 | Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase | GASTER LARAMIE MARY (GB) | 2005-01-20 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| EP-1444232-A1 | PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003042211-A1 | PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | KCNH2 4076/4885APP 1367/4885RELA 1045/4885 |
| US-20050014938-A1 | Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase | AKR1C3, CBR3, PHKG1 | KCNH2 64/4885APP 4547/4885RELA 3199/4885 |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | KCNH2 4188/4885APP 1319/4885RELA 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.